fallopian tube neoplasms/nausée

Le lien est enregistré dans le presse-papiers

Choisissez le type de tri

12 résultats

Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Recurrent ovarian, fallopian tube, and peritoneal cancers have limited potential for cure with traditional therapies. Preliminary results from a phase I study of everolimus and bevacizumab in advanced solid tumors showed it to be a promising combination. The primary objective of this

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

OBJECTIVE The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer. METHODS This was a single arm, multicenter phase II trial with overall

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

The combination of low-dose radiation therapy with PARP inhibition enhances anti-tumor efficacy through potentiating DNA damage. We combined low-dose fractionated whole abdominal radiation (LDFWAR) with ABT-888 in patients with peritoneal carcinomatosis with a dose escalation in ovarian and

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

To evaluate the safety and preliminary efficacy of demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody; potent inhibitor of the Notch pathway) in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer (EOC); and to determine the maximum tolerated

Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

A combination of cytoreductive surgery, either primary (PCS) or interval (ICS), and chemotherapy with a platinum-paclitaxel regimen is the well-accepted treatment for advanced-stage epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), and primary peritoneal serous carcinoma (PPSC), but it

Paratubal borderline serous tumors.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND While ovarian borderline tumors are common, their fallopian tube counterparts are extremely rare. We describe the first case of a serous borderline paratubal tumor with a review of the literature on paratubal and tubal low malignant potential tumors. METHODS A 26 year-old woman presented

Paratubal borderline tumor diagnosed in the adolescent period: a case report and review of the literature.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

BACKGROUND Borderline paratubal cysts are rare entities. These tumors are identified as epithelial proliferation without stromal invasion. METHODS A 19-year-old virgin patient was admitted to our clinic with abdominal pain and nausea. The sonographic evaluation showed a left adnexal mass 89 × 80 mm

Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Tamoxifen has been found to be safe and effective in gynecological cancer patients with normal renal function. However, to our knowledge, no data exist regarding its effectiveness and toxicity in gynecological cancer patients with chronic kidney disease (CKD). Therefore, we retrospectively evaluated

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

OBJECTIVE To determine the safety, gene transfer, host immune response, and pharmacokinetics of a replication-deficient adenovirus encoding human, recombinant, wild-type p53 (SCH 58500) delivered into the peritoneal cavity (i.p.) alone and sequentially in combination with platinum-based

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtansine when administered in combination with carboplatin to relapsed ovarian cancer patients. Patients with recurrent, platinum-sensitive epithelial ovarian or fallopian tube cancer were enrolled. Eligibility

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Seuls les utilisateurs enregistrés peuvent traduire des articles

Se connecter S'inscrire

Purpose: Epigenetic changes are implicated in acquired resistance to platinum. Guadecitabine is a next-generation hypomethylating agent (HMA). Here, we report the clinical results, along with pharmacokinetic (PK) and pharmacodynamic analyses of the phase I study of guadecitabine and carboplatin in

Rejoignez notre
page facebook

Herbal & Natural Medicine

La base de données d'herbes médicinales la plus complète soutenue par la science

Fonctionne en 55 langues
Cures à base de plantes soutenues par la science
Reconnaissance des herbes par image
Carte GPS interactive - étiquetez les herbes sur place (à venir)
Lisez les publications scientifiques liées à votre recherche
Rechercher les herbes médicinales par leurs effets
Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets

Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées